BioCentury
ARTICLE | Emerging Company Profile

Unifying factor in NASH

Why Jecure thinks targeting the inflammasome can address multiple NASH mechanisms

March 2, 2017 7:39 PM UTC

While most companies pursuing NASH are tackling lipid metabolism, immune cell activation or bile acid transport, Jecure Therapeutics Inc. is aiming to treat the disease by blocking activation of the inflammasome, a cellular pathway it thinks drives three intertwining arms of the disease -- hepatocyte injury, innate immunity and fibrosis.

On February 15, Jecure debuted with a $20 million series A round from sole investor Versant Ventures. ...